Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The person must give their informed consent to participate in the study
- A cervical biopsy must have shown a high-grade lesion
- The person must be between 18 and 46 years old
- The transformation zone of the cervix must be visible during a colposcopy (a close-up examination of the cervix)
- The person must not have received an HPV vaccine
- Cervical cell test (cytology) results must not show AIS, adenocarcinoma, squamous cell carcinoma, or AGC NEO (confirm with trial site for full details on which results are acceptable)
Who may not be able to join:
- Cervical cell test (cytology) results showing AIS, AGC NEO, adenocarcinoma, or squamous cell carcinoma would make a person ineligible
- People whose immune system is suppressed, for example due to medication or illness, may not be eligible
- People with an active autoimmune disease (a condition where the immune system attacks the body's own tissues) may not be eligible
- People who have previously had a procedure called cervical cryodestruction (a treatment that freezes cervical tissue) may not be eligible
- People who received an HPV vaccine before the study began may not be eligible
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lukas Rob, Prof., MUDr., Csc., Vascular surgery, University hospital Královské Vinohrady, Prague
Phone: +420 296472368
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate spontaneous regression/progression over a 2-year period according to HPV HR genotyping; To evaluate spontaneous regression/progression over a 2-year period according to methylation results; o evaluate spontaneous regression/progression over a 2-year period according to CinTec plus
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.